In:
Nanotechnology Reviews, Walter de Gruyter GmbH, Vol. 11, No. 1 ( 2022-06-20), p. 2320-2348
Abstract:
Hydrogen sulfide (H 2 S), as the third gasotransmitter, plays important roles in promoting the growth, proliferation, and metastasis of cancer cells. Recently, emerging nanotherapeutics have been developed for cancer therapy by regulating the H 2 S concentration at tumor sites. The action of H 2 S in cancer therapy can be demonstrated by a bell-shaped dose-response curve. In addition to the H 2 S donation from gas therapy, reducing the level of intratumoral H 2 S can also exert an antitumor effect by disturbing the redox balance of tumor cells. On top of that, the integration of nanotechnology further enhances the diversity of H 2 S-involved cancer treatments. As a result, phototherapy, chemotherapy, immunotherapy, and ultrasonic therapy can all be realized by designing nanotherapeutics based on the physicochemical properties of H 2 S. Furthermore, the active/passive targeting effects and onsite H 2 S-regulating ability of nanotherapeutics greatly improve the safety of treatment. To track the development and promote the clinical transformation of H 2 S-involved nanotherapeutics, this review introduced the antitumor-related properties of H 2 S gas and the evolution of H 2 S-involved cancer therapy. Then, we discussed the design concepts and mechanisms of H 2 S-involved nanotherapeutics in depth. Finally, the future expectations and challenges were spotlighted in the concept of translational medicine.
Type of Medium:
Online Resource
ISSN:
2191-9097
DOI:
10.1515/ntrev-2022-0130
Language:
English
Publisher:
Walter de Gruyter GmbH
Publication Date:
2022
detail.hit.zdb_id:
2646548-6
